Please login to the form below

Not currently logged in
Email:
Password:

Tony de Fougerolles joins Evox Therapeutics as CEO

He succeeds Dr Per Lundin who stays at the firm as COO

TonyOxford, UK-based Evox Therapeutics has appointed its new chief executive officer in the form of Tony de Fougerolles.

He succeeds Dr Per Lundin who will continue in his role as chief operating officer of the biotherapeutics company, overseeing operational aspects of its business as well as advancing and expanding the company’s intellectual property estate.

Dr Lundin said: “After a thorough selection process, I am incredibly pleased that Tony is joining the team as we continue to develop Evox into the world’s leading exosome therapeutics company.

“Tony has an outstanding track record in progressing products through the pipeline and a strong scientific understanding.

“He has also been integral to his previous companies’ deal-making success and we are exciting for him to bring such extensive experience to Evox.”

Fougerolles joins the company from Ablynx, where he held the role of chief scientific officer for four years expanding its pipeline and forming new partnerships.

Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.

He said: “Having worked as a chief scientific officer for seven years, I appreciate the fine balance between developing new drug platforms, advancing a therapeutic pipeline, and building the business.

“I believe we can progress through the clinic an entirely novel class of biotherapeutics and I look forward to working with Per and the rest of the board to develop therapies with a potentially transformative impact on the lives of patients suffering from severe illnesses.”

22nd November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics